ZHENFANZHEN FAN8715FAN, ZHENProfessorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson1901 East RoadHouston77054-3005TXAuthorship 1657131Authorship 1661193Authorship 1705296Authorship 1706514Authorship 1712123Authorship 1736692Authorship 1739885Authorship 1754373Authorship 17545110Authorship 1773005Authorship 1802295Authorship 1859984Authorship 1863825Authorship 1871584Authorship 1873004Authorship 1877006Authorship 18849515Authorship 1889674Authorship 1898603Authorship 1929904Authorship 1932125Authorship 1954995Authorship 19619748402640Fan Z, Baselga J, Masui H, Mendelsohn JCancer researchAntitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 1993 Oct 01; 53(19):4637-42.Cancer Res1993-10-01T00:00:001993Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.8622855Wu X, Rubin M, Fan Z, DeBlasio T, Soos T, Koff A, Mendelsohn JOncogeneInvolvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene. 1996 Apr 04; 12(7):1397-403.Oncogene1996-04-04T00:00:001996Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody.11304726Wang L, Liu B, Schmidt M, Lu Y, Wels W, Fan ZThe ProstateAntitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells. Prostate. 2001 Apr; 47(1):21-8.Prostate2001-04-01T00:00:002001Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells.11567823Nasu S, Ang KK, Fan Z, Milas LInternational journal of radiation oncology, biology, physicsC225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys. 2001 Oct 01; 51(2):474-7.Int J Radiat Oncol Biol Phys2001-10-01T00:00:002001C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability.14967457Milas L, Fan Z, Andratschke NH, Ang KKInternational journal of radiation oncology, biology, physicsEpidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys. 2004 Mar 01; 58(3):966-71.Int J Radiat Oncol Biol Phys2004-03-01T00:00:002004Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies.EpidemiologyExperimental TherapeuticsGenomic MedicineGynecological Oncology & Reproductive MedicineLeukemiaMolecular & Cellular OncologySystems BiologyThoracic Head & Neck Medical OncologyMD AndersonMIEN-CHIEHUNGMIEN-CHIE HUNG8427HUNG, MIEN-CHIEProfessorXIFENGWUXIFENG WU8625WU, XIFENGProfessorJOHN VICTORHEYMACHJOHN VICTOR HEYMACH9280HEYMACH, JOHN VICTORProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorGORDON BMILLSGORDON B MILLS8620MILLS, GORDON BProfessorBULENTOZPOLATBULENT OZPOLAT8675OZPOLAT, BULENTAssociate ProfessorJOHNMENDELSOHNJOHN MENDELSOHN8711MENDELSOHN, JOHNProfessor4.081280.00356471392research areas1.783320.015726139coauthor of114.84122.586860similar to1196selected publicationsANIL KSOODANIL K SOOD9048SOOD, ANIL KProfessorTIANHONGPANTIANHONG PAN9887PAN, TIANHONGInstructorAuthorship 2143701Authorship 2160242Authorship 2163586Authorship 2168022Authorship 2171952Authorship 2173678Authorship 2175573Authorship 2190545Authorship 2196885Authorship 2210676Authorship 2215714Authorship 2220956Authorship 2253834Authorship 2266016Authorship 2267065Authorship 2287485Authorship 23387257559780Fan Z, Lu Y, Wu X, DeBlasio A, Koff A, Mendelsohn JThe Journal of cell biologyProlonged induction of p21Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition. J Cell Biol. 1995 Oct; 131(1):235-42.J Cell Biol1995-10-01T00:00:001995Prolonged induction of p21Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition.9060954Mendelsohn J, Fan ZJournal of the National Cancer InstituteEpidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst. 1997 Mar 05; 89(5):341-3.J Natl Cancer Inst1997-03-05T00:00:001997Epidermal growth factor receptor family and chemosensitization.9690618Bromberg JF, Fan Z, Brown C, Mendelsohn J, Darnell JECell growth & differentiation : the molecular biology journal of the American Association for Cancer ResearchEpidermal growth factor-induced growth inhibition requires Stat1 activation. Cell Growth Differ. 1998 Jul; 9(7):505-12.Cell Growth Differ1998-07-01T00:00:001998Epidermal growth factor-induced growth inhibition requires Stat1 activation.10213228Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora GClinical cancer research : an official journal of the American Association for Cancer ResearchAntitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res. 1999 Apr; 5(4):909-16.Clin Cancer Res1999-04-01T00:00:001999Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.10473102Ye D, Mendelsohn J, Fan ZClinical cancer research : an official journal of the American Association for Cancer ResearchAndrogen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clin Cancer Res. 1999 Aug; 5(8):2171-7.Clin Cancer Res1999-08-01T00:00:001999Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells.10517171Chou JL, Fan Z, DeBlasio T, Koff A, Rosen N, Mendelsohn JBreast cancer research and treatmentConstitutive overexpression of cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor. Breast Cancer Res Treat. 1999 Jun; 55(3):267-83.Breast Cancer Res Treat1999-06-01T00:00:001999Constitutive overexpression of cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor.10690556Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan ZClinical cancer research : an official journal of the American Association for Cancer ResearchIn vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 2000 Feb; 6(2):701-8.Clin Cancer Res2000-02-01T00:00:002000In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.11461094Liu B, Fang M, Lu Y, Lu Y, Mills GB, Fan ZBritish journal of cancerInvolvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells. Br J Cancer. 2001 Jul 20; 85(2):303-11.Br J Cancer2001-07-20T00:00:002001Involvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells.12909240Liang K, Ang KK, Milas L, Hunter N, Fan ZInternational journal of radiation oncology, biology, physicsThe epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys. 2003 Sep 01; 57(1):246-54.Int J Radiat Oncol Biol Phys2003-09-01T00:00:002003The epidermal growth factor receptor mediates radioresistance.14617784Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan ZMolecular cancer therapeuticsSensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther. 2003 Nov; 2(11):1113-20.Mol Cancer Ther2003-11-01T00:00:002003Sensitization of breast cancer cells to radiation by trastuzumab.15234052Nakata E, Hunter N, Mason K, Fan Z, Ang KK, Milas LInternational journal of radiation oncology, biology, physicsC225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2004 Jul 15; 59(4):1163-73.Int J Radiat Oncol Biol Phys2004-07-15T00:00:002004C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy.16549426Li X, Lu Y, Jin W, Liang K, Mills GB, Fan ZThe Journal of biological chemistryAutophosphorylation of Akt at threonine 72 and serine 246. A potential mechanism of regulation of Akt kinase activity. J Biol Chem. 2006 May 12; 281(19):13837-13843.J Biol Chem2006-03-20T00:00:002006Autophosphorylation of Akt at threonine 72 and serine 246. A potential mechanism of regulation of Akt kinase activity.17931419Lu Y, Liang K, Li X, Fan ZMolecular cancerResponses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha. Mol Cancer. 2007 Oct 11; 6:63.Mol Cancer2007-10-11T00:00:002007Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha.18483308Li X, Lu Y, Liang K, Pan T, Mendelsohn J, Fan ZMolecular cancer therapeuticsRequirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab. Mol Cancer Ther. 2008 May; 7(5):1207-17.Mol Cancer Ther2008-05-01T00:00:002008Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab.18949375Cunningham MP, Thomas H, Marks C, Green M, Fan Z, Modjtahedi HInternational journal of oncologyCo-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. Int J Oncol. 2008 Nov; 33(5):1107-13.Int J Oncol2008-11-01T00:00:002008Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.20530239Chen M, Gu J, Delclos GL, Killary AM, Fan Z, Hildebrandt MA, Chamberlain RM, Grossman HB, Dinney CP, Wu XCarcinogenesisGenetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis. 2010 Aug; 31(8):1387-91.Carcinogenesis2010-06-07T00:00:002010Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients.23920275Lu H, Li X, Luo Z, Liu J, Fan ZMolecular cancer therapeuticsCetuximab reverses the Warburg effect by inhibiting HIF-1-regulated LDH-A. Mol Cancer Ther. 2013 Oct; 12(10):2187-99.Mol Cancer Ther2013-08-06T00:00:002013Cetuximab reverses the Warburg effect by inhibiting HIF-1-regulated LDH-A.Authorship 2401841Authorship 2409651Authorship 2428906Authorship 2434457Authorship 2434807Authorship 2437145Authorship 2445368Authorship 2448816Authorship 2459274Authorship 2475083Authorship 2493668Authorship 2531604Authorship 254443Authorship 2553742Authorship 2571687Authorship 26260117961676Fan Z, Lu Y, Wu X, Mendelsohn JThe Journal of biological chemistryAntibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem. 1994 Nov 04; 269(44):27595-602.J Biol Chem1994-11-04T00:00:001994Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells.8407944Fan Z, Mendelsohn J, Masui H, Kumar RThe Journal of biological chemistryRegulation of epidermal growth factor receptor in NIH3T3/HER14 cells by antireceptor monoclonal antibodies. J Biol Chem. 1993 Oct 05; 268(28):21073-9.J Biol Chem1993-10-05T00:00:001993Regulation of epidermal growth factor receptor in NIH3T3/HER14 cells by antireceptor monoclonal antibodies.9466487Fan Z, Mendelsohn JCurrent opinion in oncologyTherapeutic application of anti-growth factor receptor antibodies. Curr Opin Oncol. 1998 Jan; 10(1):67-73.Curr Opin Oncol1998-01-01T00:00:001998Therapeutic application of anti-growth factor receptor antibodies.10769641Fang M, Liu B, Schmidt M, Lu Y, Mendelsohn J, Fan ZAnticancer researchInvolvement of p21Waf1 in mediating inhibition of paclitaxel-induced apoptosis by epidermal growth factor in MDA-MB-468 human breast cancer cells. Anticancer Res. 2000 Jan-Feb; 20(1A):103-11.Anticancer Res2000-01-01T00:00:002000Involvement of p21Waf1 in mediating inhibition of paclitaxel-induced apoptosis by epidermal growth factor in MDA-MB-468 human breast cancer cells.11641417Schmidt M, Lu Y, Parant JM, Lozano G, Bacher G, Beckers T, Fan ZMolecular pharmacologyDifferential roles of p21(Waf1) and p27(Kip1) in modulating chemosensitivity and their possible application in drug discovery studies. Mol Pharmacol. 2001 Nov; 60(5):900-6.Mol Pharmacol2001-11-01T00:00:002001Differential roles of p21(Waf1) and p27(Kip1) in modulating chemosensitivity and their possible application in drug discovery studies.11756838Patrick CW, Zheng B, Schmidt M, Herman PS, Chauvin BP, Fan Z, Stark B, Evans GRAnnals of plastic surgeryDermal fibroblasts genetically engineered to release nerve growth factor. Ann Plast Surg. 2001 Dec; 47(6):660-5.Ann Plast Surg2001-12-01T00:00:002001Dermal fibroblasts genetically engineered to release nerve growth factor.12006546Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI, Fan Z, Pettaway C, Hicklin DJ, Shuin T, Dinney CPClinical cancer research : an official journal of the American Association for Cancer ResearchInhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res. 2002 May; 8(5):1253-64.Clin Cancer Res2002-05-01T00:00:002002Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.12055196Liu B, Peng D, Lu Y, Jin W, Fan ZThe Journal of biological chemistryA novel single amino acid deletion caspase-8 mutant in cancer cells that lost proapoptotic activity. J Biol Chem. 2002 Aug 16; 277(33):30159-64.J Biol Chem2002-06-07T00:00:002002A novel single amino acid deletion caspase-8 mutant in cancer cells that lost proapoptotic activity.12700279Liang K, Jin W, Knuefermann C, Schmidt M, Mills GB, Ang KK, Milas L, Fan ZMolecular cancer therapeuticsTargeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol Cancer Ther. 2003 Apr; 2(4):353-60.Mol Cancer Ther2003-04-01T00:00:002003Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy.15217533Andratschke NH, Dittmann KH, Mason KA, Fan Z, Liao Z, Komaki R, Ang KK, Milas LClinical lung cancerEpidermal growth factor receptor as a target to improve treatment of lung cancer. Clin Lung Cancer. 2004 May; 5(6):340-52.Clin Lung Cancer2004-05-01T00:00:002004Epidermal growth factor receptor as a target to improve treatment of lung cancer.16885373Cunningham MP, Thomas H, Fan Z, Modjtahedi HCancer researchResponses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. Cancer Res. 2006 Aug 01; 66(15):7708-15.Cancer Res2006-08-01T00:00:002006Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib.17804738Lu Y, Li X, Liang K, Luwor R, Siddik ZH, Mills GB, Mendelsohn J, Fan ZCancer researchEpidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res. 2007 Sep 01; 67(17):8240-7.Cancer Res2007-09-01T00:00:002007Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.19875696Chen M, Cassidy A, Gu J, Delclos GL, Zhen F, Yang H, Hildebrandt MA, Lin J, Ye Y, Chamberlain RM, Dinney CP, Wu XCarcinogenesisGenetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis. 2009 Dec; 30(12):2047-52.Carcinogenesis2009-12-01T00:00:002009Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk.20190183Card?-Vila M, Giordano RJ, Sidman RL, Bronk LF, Fan Z, Mendelsohn J, Arap W, Pasqualini RProceedings of the National Academy of Sciences of the United States of AmericaFrom combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway. Proc Natl Acad Sci U S A. 2010 Mar 16; 107(11):5118-23.Proc Natl Acad Sci U S A2010-02-26T00:00:002010From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway.20634405Li X, Fan ZCancer researchThe epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex. Cancer Res. 2010 Jul 15; 70(14):5942-52.Cancer Res2010-07-15T00:00:002010The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex.22498493Bristol ML, Di X, Beckman MJ, Wilson EN, Henderson SC, Maiti A, Fan Z, Gewirtz DAAutophagyDual functions of autophagy in the response of breast tumor cells to radiation: cytoprotective autophagy with radiation alone and cytotoxic autophagy in radiosensitization by vitamin D 3. Autophagy. 2012 May 01; 8(5):739-53.Autophagy2012-04-13T00:00:002012Dual functions of autophagy in the response of breast tumor cells to radiation: cytoprotective autophagy with radiation alone and cytotoxic autophagy in radiosensitization by vitamin D 3.Authorship 2633531Authorship 2637272Authorship 2639622Authorship 2639731Authorship 2643293Authorship 2644231Authorship 2655108Authorship 2656584Authorship 27045571316355Fan Z, Tang Z, Liu K, Zhou D, Lu J, Yuan A, Zhao HJournal of cancer research and clinical oncologyRadioiodinated anti-hepatocellular carcinoma (HCC) ferritin. Targeting therapy, tumor imaging and anti-antibody response in HCC patients with hepatic arterial infusion. J Cancer Res Clin Oncol. 1992; 118(5):371-6.J Cancer Res Clin Oncol1992-01-01T00:00:001992Radioiodinated anti-hepatocellular carcinoma (HCC) ferritin. Targeting therapy, tumor imaging and anti-antibody response in HCC patients with hepatic arterial infusion.7706497Wu X, Fan Z, Masui H, Rosen N, Mendelsohn JThe Journal of clinical investigationApoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest. 1995 Apr; 95(4):1897-905.J Clin Invest1995-04-01T00:00:001995Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin.8364927Fan Z, Masui H, Altas I, Mendelsohn JCancer researchBlockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1993 Sep 15; 53(18):4322-8.Cancer Res1993-09-15T00:00:001993Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.8706005Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn JCancer researchAnti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. 1996 Aug 15; 56(16):3666-9.Cancer Res1996-08-15T00:00:001996Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145.9815583Fan Z, Shang BY, Lu Y, Chou JL, Mendelsohn JClinical cancer research : an official journal of the American Association for Cancer ResearchReciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin Cancer Res. 1997 Nov; 3(11):1943-8.Clin Cancer Res1997-11-01T00:00:001997Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors.9989823Ye D, Mendelsohn J, Fan ZOncogeneAugmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene. 1999 Jan 21; 18(3):731-8.Oncogene1999-01-21T00:00:001999Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225.12171905Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CPClinical cancer research : an official journal of the American Association for Cancer ResearchAnti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res. 2002 Aug; 8(8):2714-24.Clin Cancer Res2002-08-01T00:00:002002Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.12559183Sclabas GM, Fujioka S, Schmidt C, Fan Z, Evans DB, Chiao PJJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary TractRestoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225. J Gastrointest Surg. 2003 Jan; 7(1):37-43; discussion 43.J Gastrointest Surg2003-01-01T00:00:002003Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225.16782806Liang K, Lu Y, Li X, Zeng X, Glazer RI, Mills GB, Fan ZMolecular pharmacologyDifferential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. Mol Pharmacol. 2006 Sep; 70(3):1045-52.Mol Pharmacol2006-06-16T00:00:002006Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine.Authorship 2727316Authorship 276770611161852Schmidt M, McWatters A, White RA, Groner B, Wels W, Fan Z, Bast RCGynecologic oncologySynergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2. Gynecol Oncol. 2001 Feb; 80(2):145-55.Gynecol Oncol2001-02-01T00:00:002001Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2.16036110Zhang L, Zhu H, Teraishi F, Davis JJ, Guo W, Fan Z, Fang BNeoplasia (New York, N.Y.)Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line. Neoplasia. 2005 Jun; 7(6):594-602.Neoplasia2005-06-01T00:00:002005Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line.Authorship 296811625871473Li X, Lu Y, Lu H, Luo J, Hong Y, Fan ZOncotargetAMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximab. Oncotarget. 2015 May 10; 6(13):11507-18.Oncotarget2015-05-10T00:00:002015AMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximab.12751641Vega J, Ke S, Fan Z, Wallace S, Charsangavej C, Li CPharmaceutical researchTargeting doxorubicin to epidermal growth factor receptors by site-specific conjugation of C225 to poly(L-glutamic acid) through a polyethylene glycol spacer. Pharm Res. 2003 May; 20(5):826-32.Pharm Res2003-05-01T00:00:002003Targeting doxorubicin to epidermal growth factor receptors by site-specific conjugation of C225 to poly(L-glutamic acid) through a polyethylene glycol spacer.74Professor54Instructor14Associate ProfessorOrthopaedic Oncology11459459Wen X, Wu QP, Lu Y, Fan Z, Charnsangavej C, Wallace S, Chow D, Li CBioconjugate chemistryPoly(ethylene glycol)-conjugated anti-EGF receptor antibody C225 with radiometal chelator attached to the termini of polymer chains. Bioconjug Chem. 2001 Jul-Aug; 12(4):545-53.Bioconjug Chem2001-07-01T00:00:002001Poly(ethylene glycol)-conjugated anti-EGF receptor antibody C225 with radiometal chelator attached to the termini of polymer chains.26801746Ai Z, Lu Y, Qiu S, Fan ZCancer lettersOvercoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism. Cancer Lett. 2016 Apr 01; 373(1):36-44.Cancer Lett2016-01-19T00:00:002016Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.27450723Lu H, Li X, Lu Y, Qiu S, Fan ZCancer lettersASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis. Cancer Lett. 2016 10 10; 381(1):23-30.Cancer Lett2016-07-19T00:00:002016ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.17477732Adams KE, Ke S, Kwon S, Liang F, Fan Z, Lu Y, Hirschi K, Mawad ME, Barry MA, Sevick-Muraca EMJournal of biomedical opticsComparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. J Biomed Opt. 2007 Mar-Apr; 12(2):024017.J Biomed Opt2007-03-01T00:00:002007Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer.27693630Luo J, Hong Y, Lu Y, Qiu S, Chaganty BK, Zhang L, Wang X, Li Q, Fan ZCancer lettersAcetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximab. Cancer Lett. 2017 01 01; 384:39-49.Cancer Lett2016-09-28T00:00:002016Acetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximab.Authorship 37450227621778691Wu Y, Li X, Zhu JX, Xie W, Le W, Fan Z, Jankovic J, Pan TNeuro-SignalsResveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals. 2011; 19(3):163-74.Neurosignals2011-07-22T00:00:002011Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease.22966490Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, B?nhegyi G, Bartholomew CR, Bassham DC, Bast RC, Batoko H, Bay BH, Beau I, B?chet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahov? M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Choi KS, Choi ME, Chouaib S, Choubey D, Choubey V, Chu CT, Chuang TH, Chueh SH, Chun T, Chwae YJ, Chye ML, Ciarcia R, Ciriolo MR, Clague MJ, Clark RS, Clarke PG, Clarke R, Codogno P, Coller HA, Colombo MI, Comincini S, Condello M, Condorelli F, Cookson MR, Coombs GH, Coppens I, Corbalan R, Cossart P, Costelli P, Costes S, Coto-Montes A, Couve E, Coxon FP, Cregg JM, Crespo JL, Cronj? MJ, Cuervo AM, Cullen JJ, Czaja MJ, D'Amelio M, Darfeuille-Michaud A, Davids LM, Davies FE, De Felici M, de Groot JF, de Haan CA, De Martino L, De Milito A, De Tata V, Debnath J, Degterev A, Dehay B, Delbridge LM, Demarchi F, Deng YZ, Dengjel J, Dent P, Denton D, Deretic V, Desai SD, Devenish RJ, Di Gioacchino M, Di Paolo G, Di Pietro C, D?az-Araya G, D?az-Laviada I, Diaz-Meco MT, Diaz-Nido J, Dikic I, Dinesh-Kumar SP, Ding WX, Distelhorst CW, Diwan A, Djavaheri-Mergny M, Dokudovskaya S, Dong Z, Dorsey FC, Dosenko V, Dowling JJ, Doxsey S, Dreux M, Drew ME, Duan Q, Duchosal MA, Duff K, Dugail I, Durbeej M, Duszenko M, Edelstein CL, Edinger AL, Egea G, Eichinger L, Eissa NT, Ekmekcioglu S, El-Deiry WS, Elazar Z, Elgendy M, Ellerby LM, Eng KE, Engelbrecht AM, Engelender S, Erenpreisa J, Escalante R, Esclatine A, Eskelinen EL, Espert L, Espina V, Fan H, Fan J, Fan QW, Fan Z, Fang S, Fang Y, Fanto M, Fanzani A, Farkas T, Farr? JC, Faure M, Fechheimer M, Feng CG, Feng J, Feng Q, Feng Y, F?s?s L, Feuer R, Figueiredo-Pereira ME, Fimia GM, Fingar DC, Finkbeiner S, Finkel T, Finley KD, Fiorito F, Fisher EA, Fisher PB, Flajolet M, Florez-McClure ML, Florio S, Fon EA, Fornai F, Fortunato F, Fotedar R, Fowler DH, Fox HS, Franco R, Frankel LB, Fransen M, Fuentes JM, Fueyo J, Fujii J, Fujisaki K, Fujita E, Fukuda M, Furukawa RH, Gaestel M, Gailly P, Gajewska M, Galliot B, Galy V, Ganesh S, Ganetzky B, Ganley IG, Gao FB, Gao GF, Gao J, Garcia L, Garcia-Manero G, Garcia-Marcos M, Garmyn M, Gartel AL, Gatti E, Gautel M, Gawriluk TR, Gegg ME, Geng J, Germain M, Gestwicki JE, Gewirtz DA, Ghavami S, et alAutophagyGuidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr; 8(4):445-544.Autophagy2012-04-01T00:00:002012Guidelines for the use and interpretation of assays for monitoring autophagy.27074568Lu Y, Shi C, Qiu S, Fan ZOncotargetIdentification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells. Oncotarget. 2016 Oct 04; 7(40):64766-64777.Oncotarget2016-10-04T00:00:002016Identification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells.27141382Chaganty BK, Lu Y, Qiu S, Somanchi SS, Lee DA, Fan ZOncoimmunologyTrastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFN? secretion. Oncoimmunology. 2016 Apr; 5(4):e1100790.Oncoimmunology2015-10-29T00:00:002015Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFN? secretion.Authorship 842937Authorship 843390Authorship 848570Authorship 849775Authorship 853362Authorship 853845Authorship 855778Authorship 856274Authorship 856450Authorship 860838Authorship 865844Authorship 866708Acta Academiae Medicinae ShanghaiDetection of anti-antibody in serum of patient with hepatocellular carcinoma following radioimmunotherapy. Acta Academiae Medicinae Shanghai. 17:451-453.Detection of anti-antibody in serum of patient with hepatocellular carcinoma following radioimmunotherapyOncotargetAMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximab. Oncotarget. 6:11507-11518.AMPK-mediated energy homeostasis and associated metabolic effects on cancer cell response and resistance to cetuximabCancer LettersASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis. Cancer Letters. 381:23-30.ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosisActa Academiae Medicinae ShanghaiRadioimmunoimaging of primary liver cancer in patients with <sup>131</sup>I labeled anti-human hepatocellular carcinoma isoferritin antibody. Acta Academiae Medicinae Shanghai. 17:405-408.Radioimmunoimaging of primary liver cancer in patients with <sup>131</sup>I labeled anti-human hepatocellular carcinoma isoferritin antibodyOncoImmunologyTrastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNγ secretion. OncoImmunology. 5.Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNγ secretionBreast Cancer Research and TreatmentRole of AKT in chemotherapy-mediated cytotoxicity in MCF-7 breast cancer cells. Breast Cancer Research and Treatment. 69:275.Role of AKT in chemotherapy-mediated cytotoxicity in MCF-7 breast cancer cellsChinese Journal of Cancer ResearchFactors influencing the effect of radioimmunotherapy on liver cancer. Chinese Journal of Cancer Research. 4:55-60.Factors influencing the effect of radioimmunotherapy on liver cancerAntibody, Immunoconjugates, and RadiopharmaceuticalsA decade's studies on the immunotargeting therapy of hepatocellular carcinoma. Antibody, Immunoconjugates, and Radiopharmaceuticals. 6:155-165.A decade's studies on the immunotargeting therapy of hepatocellular carcinomaCancer LettersOvercoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism. Cancer Letters. 373:36-44.Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolismCancer LettersAcetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximab. Cancer Letters. 384:39-49.Acetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximabOncotargetIdentification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cells. Oncotarget. 7:64766-64777.Identification and validation of COX-2 as a co-target for overcoming cetuximab resistance in colorectal cancer cellsBritish Journal of CancerAcquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. British Journal of Cancer. 113:1010-1019.Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers21266059Zhang G, Brewster A, Guan B, Fan Z, Brown PH, Xu XCBMC cancerTumor-suppressor activity of RRIG1 in breast cancer. BMC Cancer. 2011 Jan 25; 11:32.BMC Cancer2011-01-25T00:00:002011Tumor-suppressor activity of RRIG1 in breast cancer.21802425Guo W, Chen D, Fan Z, Epstein HFJournal of molecular biologyDifferential turnover of myosin chaperone UNC-45A isoforms increases in metastatic human breast cancer. J Mol Biol. 2011 Sep 23; 412(3):365-78.J Mol Biol2011-07-23T00:00:002011Differential turnover of myosin chaperone UNC-45A isoforms increases in metastatic human breast cancer.28823958Tao X, Lu Y, Qiu S, Wang Y, Qin J, Fan ZCancer lettersAP1G1 is involved in cetuximab-mediated downregulation of ASCT2-EGFR complex and sensitization of human head and neck squamous cell carcinoma cells to ROS-induced apoptosis. Cancer Lett. 2017 11 01; 408:33-42.Cancer Lett2017-08-18T00:00:002017AP1G1 is involved in cetuximab-mediated downregulation of ASCT2-EGFR complex and sensitization of human head and neck squamous cell carcinoma cells to ROS-induced apoptosis.Authorship 8873184Authorship 8877014Authorship 8877156Authorship 8877359Authorship 8880705Authorship 8885936D000911Chemicals & Drugs99043510.391387Antibodies, MonoclonalD019008Physiology92951790.363934Drug Resistance, NeoplasmAuthorship 9127577Authorship 9251324Authorship 928293827631517Nicolae A, Ganapathi KA, Pham TH, Xi L, Torres-Cabala CA, Nanaji NM, Zha HD, Fan Z, Irwin S, Pittaluga S, Raffeld M, Jaffe ESThe American journal of surgical pathologyEBV-negative Aggressive NK-cell Leukemia/Lymphoma: Clinical, Pathologic, and Genetic Features. Am J Surg Pathol. 2017 01; 41(1):67-74.Am J Surg Pathol2017-01-01T00:00:002017EBV-negative Aggressive NK-cell Leukemia/Lymphoma: Clinical, Pathologic, and Genetic Features.29746929Chaganty BKR, Qiu S, Gest A, Lu Y, Ivan C, Calin GA, Weiner LM, Fan ZCancer lettersTrastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN? secretion. Cancer Lett. 2018 08 28; 430:47-56.Cancer Lett2018-05-08T00:00:002018Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN? secretion.29858032Meng S, Wang G, Lu Y, Fan ZLung cancer (Amsterdam, Netherlands)Functional cooperation between HIF-1a and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR. Lung Cancer. 2018 07; 121:82-90.Lung Cancer2018-05-01T00:00:002018Functional cooperation between HIF-1a and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.D051795Chemicals & Drugs2343770.836559Hypoxia-Inducible Factor 1, alpha SubunitD0000688181724710.850529CetuximabD066246Chemicals & Drugs63422980.527591ErbB Receptors12761490Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan ZOncogeneHER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 2003 May 22; 22(21):3205-12.Oncogene2003-05-22T00:00:002003HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.15806152Luwor RB, Lu Y, Li X, Mendelsohn J, Fan ZOncogeneThe antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene. 2005 Jun 23; 24(27):4433-41.Oncogene2005-06-23T00:00:002005The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression.16168102Li X, Lu Y, Liang K, Liu B, Fan ZBreast cancer research : BCRDifferential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells. Breast Cancer Res. 2005; 7(5):R589-97.Breast Cancer Res2005-05-24T00:00:002005Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells.20864811Li X, Lu Y, Pan T, Fan ZAutophagyRoles of autophagy in cetuximab-mediated cancer therapy against EGFR. Autophagy. 2010 Nov; 6(8):1066-77.Autophagy2010-11-01T00:00:002010Roles of autophagy in cetuximab-mediated cancer therapy against EGFR.21075308Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, Fan ZCancer cellRecombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell. 2010 Nov 16; 18(5):423-35.Cancer Cell2010-11-16T00:00:002010Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation.21209911Lu Y, Li X, Lu H, Fan ZPloS one1, 9-Pyrazoloanthrones downregulate HIF-1a and sensitize cancer cells to cetuximab-mediated anti-EGFR therapy. PLoS One. 2010 Dec 29; 5(12):e15823.PLoS One2010-12-29T00:00:0020101, 9-Pyrazoloanthrones downregulate HIF-1a and sensitize cancer cells to cetuximab-mediated anti-EGFR therapy.21411223Luwor RB, Lu Y, Li X, Liang K, Fan ZCancer lettersConstitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib. Cancer Lett. 2011 Jul 01; 306(1):85-91.Cancer Lett2011-03-15T00:00:002011Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib.22348829Lu H, Liang K, Lu Y, Fan ZCancer lettersThe anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1a. Cancer Lett. 2012 Sep 01; 322(1):78-85.Cancer Lett2012-02-17T00:00:002012The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1a.23291984Ai M, Liang K, Lu Y, Qiu S, Fan ZCancer biology & therapyBrk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition. Cancer Biol Ther. 2013 Mar; 14(3):237-45.Cancer Biol Ther2013-01-04T00:00:002013Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition.23474495Xu J, Lu Y, Qiu S, Chen ZN, Fan ZCancer lettersA novel role of EMMPRIN/CD147 in transformation of quiescent fibroblasts to cancer-associated fibroblasts by breast cancer cells. Cancer Lett. 2013 Jul 28; 335(2):380-6.Cancer Lett2013-03-06T00:00:002013A novel role of EMMPRIN/CD147 in transformation of quiescent fibroblasts to cancer-associated fibroblasts by breast cancer cells.23707532Ai M, Qiu S, Lu Y, Fan ZCellular signallingHER2 regulates Brk/PTK6 stability via upregulating calpastatin, an inhibitor of calpain. Cell Signal. 2013 Sep; 25(9):1754-61.Cell Signal2013-05-22T00:00:002013HER2 regulates Brk/PTK6 stability via upregulating calpastatin, an inhibitor of calpain.Authorship 956327631578313Lu H, Lu Y, Xie Y, Qiu S, Li X, Fan ZJCI insightRational combination with PDK1 inhibition overcomes cetuximab resistance in head and neck squamous cell carcinoma. JCI Insight. 2019 10 03; 4(19).JCI Insight2019-10-03T00:00:002019Rational combination with PDK1 inhibition overcomes cetuximab resistance in head and neck squamous cell carcinoma.Authorship 1033618634731283Chaganty BKR, Qiu S, Lu Y, Lopez-Berestein G, Ozpolat B, Fan ZCancer immunology, immunotherapy : CIIRedirecting host preexisting influenza A virus immunity for cancer immunotherapy. Cancer Immunol Immunother. 2022 Jul; 71(7):1611-1623.Cancer Immunol Immunother2021-11-03T00:00:002021Redirecting host preexisting influenza A virus immunity for cancer immunotherapy.Authorship 10693801337140477Wu C, Emley B, Zhao L, Liang Y, Ai Q, Chen Z, Robles Hern?ndez FC, Wang F, Risal S, Guo H, Lou J, Yao Y, Fan ZNano lettersUnderstanding the Chemomechanical Function of the Silver-Carbon Interlayer in Sheet-type All-Solid-State Lithium-Metal Batteries. Nano Lett. 2023 May 24; 23(10):4415-4422.Nano Lett2023-05-04T00:00:002023Understanding the Chemomechanical Function of the Silver-Carbon Interlayer in Sheet-type All-Solid-State Lithium-Metal Batteries.Authorship 1073850837224260Feng G, Shi Y, Jia H, Risal S, Yang X, Ruchhoeft P, Shih WC, Fan Z, Xu W, Shan XScience advancesProgressive and instantaneous nature of lithium nucleation discovered by dynamic and operando imaging. Sci Adv. 2023 May 24; 9(21):eadg6813.Sci Adv2023-05-24T00:00:002023Progressive and instantaneous nature of lithium nucleation discovered by dynamic and operando imaging.Authorship 1078583737613571Wu C, Zhao L, Ai Q, Risal S, Lou J, Yao Y, Fan ZMicroscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of CanadaIn situ Observation of Lithium Stripping and Plating Process in an Open-cell All-solid-state Lithium Metal Battery. Microsc Microanal. 2023 Jul 22; 29(Supplement_1):1287-1288.Microsc Microanal2023-07-22T00:00:002023In situ Observation of Lithium Stripping and Plating Process in an Open-cell All-solid-state Lithium Metal Battery.Authorship 1081272737820636Wang F, Zhou B, Wang R, Jenkinson J, Zhu W, Zhong J, Fan Z, Sun LNanotechnologyEngineering microcracks in MWCNT/elastomer bilayers for high-performance stretchable sensor development. Nanotechnology. 2023 Oct 30; 35(3).Nanotechnology2023-10-30T00:00:002023Engineering microcracks in MWCNT/elastomer bilayers for high-performance stretchable sensor development.true1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1InstructorInstructor24100272Liang K, Qiu S, Lu Y, Fan ZCancer biology & therapyAutocrine/paracrine erythropoietin regulates migration and invasion potential and the stemness of human breast cancer cells. Cancer Biol Ther. 2014 Jan; 15(1):89-98.Cancer Biol Ther2013-10-22T00:00:002013Autocrine/paracrine erythropoietin regulates migration and invasion potential and the stemness of human breast cancer cells.